COMPARATIVE EFFICACY AND SAFETY OF RIVAROXABAN-BASED DUAL-PATHWAY ANTITHROMBOTIC THERAPY VERSUS DUAL ANTIPLATELET THERAPY: A POOLED ANALYSIS OF CONTEMPORARY RANDOMIZED CONTROLLED TRIALS

COMPARATIVE EFFICACY AND SAFETY OF RIVAROXABAN-BASED DUAL-PATHWAY ANTITHROMBOTIC THERAPY VERSUS DUAL ANTIPLATELET THERAPY: A POOLED ANALYSIS OF CONTEMPORARY RANDOMIZED CONTROLLED TRIALS

Methods Data were extracted from published results of four landmark trials involving low-dose rivaroxaban (R; 2.5 mg twice daily) plus single antiplatelet therapy (SAPT; aspirin or P2Y12 inhibitor) or DAPT: Adding R to DAPT was not associated with an incremental benefit in ischemia prevention but wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A38-A38
Hauptverfasser: Jamil, Adeel, Jamil, Umer, Faggioni, Michela, Marszalek, Jolanta, Mehrsefat, Sara, Pahlavani, Seyedmahdi, Talib, Usama, Karimi, Zahra, Radulovic, Miroslav, Chi, Gerald, Peters, James J.
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods Data were extracted from published results of four landmark trials involving low-dose rivaroxaban (R; 2.5 mg twice daily) plus single antiplatelet therapy (SAPT; aspirin or P2Y12 inhibitor) or DAPT: Adding R to DAPT was not associated with an incremental benefit in ischemia prevention but with a greater risk of major or intracranial hemorrhage.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(18)30579-5